This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Pilot studies with recombinant tissue plasminogen activator (rtPA) for acute ischemic stroke suggested that early clot lysis can be performed with acceptable safety. If thrombolytic recanalization of occluded arteries can be performed before the infarction process has been completed, it may reduce the degree of ischemic injury to the brain. The North American perspective on thrombolytic therapy with rtPA in acute ischemic stroke is derived largely from these early pilot studies and the results of the phase III trial conducted by the National Institute of Neurological Disorders and Stroke(NINDS) rtPA Stroke Study group.1 On the basis of the NINDS study results, in mid-1996 the US Food and Drug Administration (FDA) advisory committee voted unanimously to recommend approval. The FDA approval followed rapidly for treatment of patients within 3 hours after onset of acute ischemic stroke. This article reviews the design and results of that study and its impact on current attitudes toward the management of patients with acute ischemic stroke in North America.
NINDS trial design. The NINDS trial was a phase III, multicenter, randomized, placebo-controlled, double-blind study conducted in eight centers in the United States. It was divided into two parts and enrolled a total of 624 patients in the combined study. The first part of the study was designed to assess whether patients receiving rtPA achieved significant early improvement in neurologic deficits compared to those receiving placebo. Early improvement was defined as complete resolution of the neurologic deficit or an improvement from baseline of 4 or more points on the National Institutes of Health Stroke Scale (NIHSS) 24 hours after the onset of stroke.
The second, pivotal part of the NINDS trial was an outcomes study that assessed whether treatment with rtPA reduced the chance of disability in those receiving rtPA compared with those receiving placebo measured …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Cutaneous α-Synuclein Signatures in Patients With Multiple System Atrophy and Parkinson Disease
Dr. Rizwan S. Akhtar and Dr. Sarah Brooker